Heyholder
‹ Activism Filings

Xcell Therapeutics Inc. Q3 revenue KRW 1.1 billion, operating loss KRW 3.0 billion

Xcell Therapeutics Inc.· Periodic Report

AI summary · Not investment advice

Excel Therapeutics sold KRW 1.1 billion in Q3 and lost KRW 3.0 billion from its main business, versus a KRW 2.4 billion loss a year earlier.

Operating profit · 3 months

KRW -3.0 billion

Key facts

Revenue (3 months)
KRW 1.1 billion
Net income (3 months)
KRW -3.1 billion
Period
Q3 (cumulative 2026.01.01 ~ 2026.09.30)
Revenue (prior-year 3 months)
KRW 334.6 million
Revenue (year to date)
KRW 4.0 billion
Operating profit (prior-year 3 months)
KRW -2.4 billionOperating loss
Operating profit (year to date)
KRW -8.7 billionOperating loss
Net income (prior-year 3 months)
KRW -2.3 billionQuarterly net loss
Net income (year to date)
KRW -8.7 billionQuarterly net loss

Commentary

AI commentary · Not investment advice

What happened

Excel Therapeutics reported its third-quarter results on a consolidated basis. Sales for the latest 3 months were KRW 1.06 billion. That is up 217.9% from the same 3 months a year earlier (KRW 334.6 million) and down 45.1% from the previous quarter.

In the company's terms

Operating profit (profit from the core business) was a loss of KRW 2.98 billion for the 3 months. A year earlier, the loss was KRW 2.38 billion. Net income, the final profit after everything, was a loss of KRW 3.06 billion. A year earlier, the net loss was KRW 2.31 billion.

What changes for shareholders

For the cumulative period from Jan 1 to Sep 30, sales were KRW 4.02 billion. Operating profit was a loss of KRW 8.65 billion. Net income was a loss of KRW 8.75 billion.

Comments

No comments yet

Comments from shareholders will appear here.